Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

BACKGROUND: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents. MATERIAL AND METHODS...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ESMO Open
Hlavní autoři: Iivanainen, Sanna, Ahvonen, Jarkko, Knuuttila, Aija, Tiainen, Satu, Koivunen, Jussi Pekka
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735669/
https://ncbi.nlm.nih.gov/pubmed/31555483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000531
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky